A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer
Public ClinicalTrials.gov record NCT04844073. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (Also Known as MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients With Unresectable Locally Advanced or Metastatic Cancer
Study identification
- NCT ID
- NCT04844073
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Takeda
- Industry
- Enrollment
- 95 participants
Conditions and interventions
Conditions
Interventions
- TAK-186 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 7, 2021
- Primary completion
- Jun 16, 2025
- Completion
- Jun 16, 2025
- Last update posted
- Dec 3, 2025
2021 – 2025
United States locations
- U.S. sites
- 15
- U.S. states
- 13
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UC San Diego Moores Cancer Center | San Diego | California | 92037 | — |
| University of California San Francisco | San Francisco | California | 94143 | — |
| University of Colorado - Anschutz Medical Campus - PPDS | Aurora | Colorado | 80045-2517 | — |
| Yale University | New Haven | Connecticut | 06510-3206 | — |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20007 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Northwestern University | Chicago | Illinois | 60611-2814 | — |
| Indiana University | Indianapolis | Indiana | 43202 | — |
| University of Minnesota Medical Center, Fairview | Minneapolis | Minnesota | 55414-2959 | — |
| Columbia University Medical Center -161 Fort Washington | New York | New York | 10032 | — |
| Novant Health Cancer Institute - Elizabeth Head and Neck | Charlotte | North Carolina | 28204-3282 | — |
| Sanford Cancer Center | Sioux Falls | South Dakota | 57105-1521 | — |
| Mary Crowley Cancer Research Centers Medical City - SCRI - PPDS | Dallas | Texas | 75230 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030-4000 | — |
| Fred Hutchinson Cancer Research Center - 1100 Fairview Ave N | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04844073, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 3, 2025 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04844073 live on ClinicalTrials.gov.